If testing continues yielding positive results as hoped, Aimovig won’t be the only anti-chronic migraine drug out on the market. The U. S.…
If testing continues yielding positive results as hoped, Aimovig won’t be the only anti-chronic migraine drug out on the market.
The U. S. Food and Drug Administration announced on Thursday that it approved the drug Aimovig, a monthly form of medication that is said to be the first drug designed to combat chronic migraines.
At a yearly cost of $6,900 without insurance, Aimovig won’t come cheap once it is made available to consumers. That also means it’s going to cost almost $600 each time users inject themselves with the medication by using a pen-like device. However, research on the new anti-migraine drug revealed those that took Aimovig suffered from such headaches at a much lower monthly rate than they used to, with patients only getting an average of four migraines a month instead of the usual eight. In some cases, patients even reported that they didn’t suffer from any migraines at all, according to Amgen research doctor Sean Harper.
The above stats were in contrast to the participants who were given a placebo, as their number of monthly migraines decreased by just two. While subjects in both groups experienced minor side effects, these were described as similar, and nothing more serious than colds or respiratory infections.
The FDA approved a new migraine drug from Amgen and Novartis https://t.co/5Z9OwLz8dN
— The Wall Street Journal (@WSJ) May 18,2018
As explained by the National Institute of Neurological Disorders and Stroke website, migraines are especially intense headaches that are characterized by intense and throbbing pain, nausea and/or vomiting, visual disturbances, and sensitivity to light and sound; migraines are also about three times more common in women than they are in men.
